Kilambi News
Thursday, November 19, 2026

CMA threatens phase two probe of Vivisol Air Liquide deal

Life Sciences Thursday, November 19, 2026 - Updated Nov 19, 2026 02:42

The UK Competition and Markets Authority said on Thursday that Vivisol's anticipated acquisition of Air Liquide Healthcare's home oxygen services business may be expected to substantially lessen competition in the UK, and will be referred for a phase two investigation unless the parties offer an acceptable undertaking.

Why it matters: Home oxygen is an essential service supplied to patients at home, so a phase two referral would put the combination of two UK providers under in-depth scrutiny before it can proceed.

Data as of UK Competition and Markets Authority case page, read in full in this run: phase 1 decision announced November 19, 2026. Developing item.

The UK Competition and Markets Authority announced its phase 1 decision on Thursday in the anticipated acquisition by Dolby Medical Home Respiratory Care Limited, trading as Vivisol, of Air Liquide Healthcare Limited’s home oxygen services business. The CMA decided, on the evidence currently available to it, that it is or may be the case that the merger may be expected to result in a substantial lessening of competition within a market in the UK.

The merger will be referred for an in-depth phase 2 investigation unless the parties offer an acceptable undertaking to address the competition concerns, the CMA said. The inquiry was launched on September 24, 2026, after an invitation to comment that ran from August 11 to October 1, 2026.

Sources

  1. Vivisol / Air Liquide (home oxygen services business) merger inquiry - UK Competition and Markets Authority - 2026-11-19